Pindolol - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for pindolol and what is the scope of freedom to operate?
Pindolol
is the generic ingredient in two branded drugs marketed by Ani Pharms, Aurobindo Pharma Usa, Cosette, Mpp Pharma, Mylan Pharms Inc, Nostrum Labs, Purepac Pharm, Sun Pharm Industries, Unichem, Watson Labs, Zydus Pharms, and Novartis, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.There are eleven drug master file entries for pindolol. Seven suppliers are listed for this compound.
Summary for pindolol
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 12 |
| NDAs: | 15 |
| Drug Master File Entries: | 11 |
| Finished Product Suppliers / Packagers: | 7 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 18 |
| Patent Applications: | 6,576 |
| Drug Prices: | Drug price trends for pindolol |
| What excipients (inactive ingredients) are in pindolol? | pindolol excipients list |
| DailyMed Link: | pindolol at DailyMed |
Recent Clinical Trials for pindolol
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| SCIRENT Clinical Research and Science d.o.o. | PHASE2 |
| Actimed Therapeutics Ltd | PHASE2 |
| Scotmann Pharmaceuticals | Phase 3 |
Pharmacology for pindolol
| Drug Class | beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists |
Medical Subject Heading (MeSH) Categories for pindolol
Anatomical Therapeutic Chemical (ATC) Classes for pindolol
US Patents and Regulatory Information for pindolol
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nostrum Labs | PINDOLOL | pindolol | TABLET;ORAL | 074474-002 | Oct 28, 1996 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Cosette | PINDOLOL | pindolol | TABLET;ORAL | 074123-002 | Apr 17, 1997 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aurobindo Pharma Usa | PINDOLOL | pindolol | TABLET;ORAL | 074019-001 | Sep 3, 1992 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Zydus Pharms | PINDOLOL | pindolol | TABLET;ORAL | 209866-001 | Aug 18, 2017 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for pindolol
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | VISKEN | pindolol | TABLET;ORAL | 018285-001 | Sep 3, 1982 | ⤷ Start Trial | ⤷ Start Trial |
| Novartis | VISKEN | pindolol | TABLET;ORAL | 018285-002 | Sep 3, 1982 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch